

WO9944989

Publication Title:

MATRIX METALLOPROTEINASE INHIBITORS

Abstract:

Abstract of WO9944989


The present invention relates to compounds of formula (I) wherein X is a -CO₂H or -CONHOH group; Y and Z are independently sulphur or oxygen, at least one being sulphur; R₁ is hydrogen, hydroxy, (C1-C6)alkyl, (C2-C6)alkenyl, or (C3-C8)cycloalkyl; R₂ is a (C1-C24)alkyl, phenyl(C1-C6)alkyl, or phenyl(C0-C6 alkyl)O(C1-C6)alkyl, any of which may be optionally substituted by (C1-C6)alkyl, (C1-C6)alkoxy, halo or cyano (CN); R₃ is the characterising side chain of a natural alpha -amino acid in which any functional groups may be protected, (C1-C6)alkyl which may be optionally substituted, or cycloalkyl(C1-C6)alkyl; R₄ is hydrogen, (C1-C6)alkyl, phenyl(C1-C6)alkyl, optionally substituted phenyl or heteroaryl, or a group of formula -(Q-O)_n-Q where Q is a straight or branched (C1-C6)alkyl, where n is an integer >1 and no continuous linear sequence of atoms in the group R₄ is >12; any of the above alkyl or alkenyl being straight or branched; or a salt, hydrate or solvate thereof. The compounds of the invention are useful in the human and veterinary practice. Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 327/42, 327/44, C07D 209/20, A61K 31/16, 31/195, 31/655		A1	(11) International Publication Number: WO 99/44989
			(43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: PCT/DK99/00072 (22) International Filing Date: 23 February 1999 (23.02.99) (30) Priority Data: 9804504.0 3 March 1998 (03.03.98) GB (71) Applicant (for all designated States except US): LEO PHARMACEUTICAL PRODUCTS LTD. A/S [DK/DK]; (Løvens Kemiske Fabrik Produktionsaktieselskab), Industriparken 55, DK-2750 Ballerup (DK). (72) Inventor; and (75) Inventor/Applicant (for US only): CHRISTENSEN, Mette, Knak [DK/DK]; Kollemosevej 33 F, 1., DK-2840 Holte (DK). (74) Agent: LARSEN, Marianne, Spanget; Leo Pharmaceutical Products Ltd. A/S, Patent Dept., Industriparken 55, DK-2750 Ballerup (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	

(54) Title: **MATRIX METALLOPROTEINASE INHIBITORS**

(57) Abstract

The present invention relates to compounds of formula (I) wherein X is a $-\text{CO}_2\text{H}$ or $-\text{CONHOH}$ group; Y and Z are independently sulphur or oxygen, at least one being sulphur; R_1 is hydrogen, hydroxy, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_3-C_8) cycloalkyl; R_2 is a $(\text{C}_1-\text{C}_{24})$ alkyl, phenyl (C_1-C_6) alkyl, or phenyl (C_0-C_6) alkyl $\text{O}(\text{C}_1-\text{C}_6)$ alkyl, any of which may be optionally substituted by (C_1-C_6) alkyl, (C_1-C_6) alkoxy, halo or cyano (CN); R_3 is the characterising side chain of a natural α -amino acid in which any functional groups may be protected, (C_1-C_6) alkyl which may be optionally substituted, or cycloalkyl (C_1-C_6) alkyl; R_4 is hydrogen, (C_1-C_6) alkyl, phenyl (C_1-C_6) alkyl, optionally substituted phenyl or heteroaryl, or a group of formula $-(\text{Q}-\text{O})_n-\text{Q}$ where Q is a straight or branched (C_1-C_6) alkyl, where n is an integer >1 and no continuous linear sequence of atoms in the group R_4 is >12 ; any of the above alkyl or alkenyl being straight or branched; or a salt, hydrate or solvate thereof. The compounds of the invention are useful in the human and veterinary practice.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Matrix Metalloproteinase Inhibitors

This invention comprises new matrix metalloproteinase inhibitors, which are
5 succinamide based hydroxamic acid or carboxylic acid thioamides. The invention
further comprises processes for their preparation, pharmaceutical compositions
containing them, and the use of such compounds in medicine. In particular, the
compounds are inhibitors of matrix metalloproteinases involved in tissue degrada-
tion. Some of the compounds of the invention are, in addition, inhibitors of the
10 release of tumour necrosis factor- α (TNF- α) from cells.

Background of the Invention

Matrix metalloproteinases (MMPs) are a family of zinc endopeptidases, which
15 exhibit proteolytic activity towards most if not all of the constituents of the extra-
cellular matrix, such as the interstitial and basement membrane collagens, fibro-
nectin, and laminin. They play a key role in both physiological and pathological
tissue degradation.

At least 16 different and yet highly homologous MMP-species have been
20 characterised. They share a catalytic domain with the HisGluXaaGlyHis motif
responsible for ligating zinc, which is essential for the catalytic function. MMP
family members differ from each other structurally by the presence or absence of
additional domains that contribute to activities, such as substrate specificity, inhibitor
binding, matrix binding and cell-surface localisation. [H. Birkedal-Hansen; W. G.
25 Moore; M. K. Boddien; C. J. Windsor; B. Birkedal-Hansen; A. DeCarlo: *Crit. Rev.*
Oral Biol. Med. (1993) 4, 197-250 and A. F. Chambers; L. M. Matristan: *J. Natl.*
Cancer Inst. (1997) 89(17), 1260-1270]. There are three major groups of MMPs,
identified by their substrate preferences: collagenases degrade fibrillar collagen,
stromelysins prefer proteoglycans and glycoproteins as substrates and gelatinases are
30 particularly potent in degradation of nonfibrillar and denatured collagens (gelatine).

Compounds which have the property of inhibiting the action of matrix metalloproteinases are thought to be potentially useful for the treatment or prophylaxis of conditions involving tissue breakdown and inflammation, for example rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, and tumour metastasis, invasion and growth. MMP inhibitors are also of potential value in the treatment of neuro-inflammatory disorders, including those involving myelin degradation, for example multiple sclerosis, as well as in the management of angiogenesis dependent diseases, which include arthritic conditions and solid tumour growth as well as psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angiofibromas and hemangiomas. However, the relative contributions of individual MMPs in any of the above disease states is not yet fully understood.

TNF- α is a cytokine which is produced as a 28-kDa precursor and released in an active 17-kDa form. This active form can mediate a large number of deleterious effects *in vivo*, including inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase responses, similar to those seen during acute infections and shock states. Chronic administration of TNF- α can cause cachexia and anorexia; accumulation of excess TNF- α can be fatal.


Compounds which inhibit the production or action of TNF- α are therefore thought to be potentially useful for the treatment or prophylaxis of many inflammatory, infectious, immunological and malignant diseases. These include, but are not limited to, septic shock, haemodynamic shock and sepsis syndrome, post ischaemic reperfusion injury, malaria, Crohn's disease, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, rheumatoid arthritis, multiple sclerosis, radiation damage, toxicity following administration of immunosuppressive monoclonal antibodies and hyperoxic alveolar injury.

TNF- α convertase is a metalloprotease involved in the biosynthesis of TNF- α . Inhibition of TNF- α convertase inhibits production of TNF- α . Since excessive TNF- α production has been noted in several disease conditions characterised by

MMP-mediated tissue degradation, including multiple sclerosis, arthritis and cancer, compounds which inhibit both MMPs and TNF- α production may have particular advantages in the treatment or prophylaxis of diseases or conditions in which both mechanisms are involved.

5 Many known MMP inhibitors are peptide derivatives, based on naturally occurring amino acids, and are analogues of the cleavage sites in the natural substrates of the MMPs. Other known MMP inhibitors are less peptidic in structure, and may be viewed as pseudopeptides or peptidomimetics. Such compounds usually have a zinc binding group, which most often is a hydroxamic acid, carboxylic acid,
10 sulphhydryl, and oxygenated phosphorous (e.g. phosphinic acid and phosphonamides including aminophosphonic acid) groups.

Two known classes of pseudopeptide or peptidomimetic MMP inhibitors have a hydroxamic acid group and a carboxylic acid group, respectively, as their zinc binding groups. With few exceptions, such known inhibitors may be represented by
15 the structural formula (A)



in which X is the zinc binding hydroxamic acid (-CONHOH) or carboxylic acid (-COOH) group and the groups R₁ to R₅ are variable in accordance with the specific
20 prior art disclosures of such compounds.

In such compounds, it is generally understood in the art that the variation of the zinc binding group and the substituents R₁, R₂ and R₃ can have an appreciable effect on the relative inhibition of the MMPs. The group X is thought to interact with
25 MMPs by binding to a Zn(II) ion in the active site. Generally the hydroxamic acid is preferred over the carboxylic acid in terms of inhibitory activity against the various MMPs. However, the carboxylic acid moiety in combination with other substituents


can provide selective inhibition of gelatinase (EP-489,577-A). The R₁, R₂ and R₃ groups are believed to occupy, respectively, the P1, P1' and P2' amino acid side chain binding sites for the natural enzyme substrates. There is evidence that a larger R₁ substituent can enhance activity against stromelysin, and that a (C₁-C₆)alkyl group (such as isobutyl) at R₂ may be preferred for activity against collagenase whilst a phenylalkyl group (such as phenylpropyl) at R₂ may provide selectivity for gelatinase over the other MMPs.

Although numerous MMP inhibitors with potent *in vitro* activities are known, many have not been suitable for further development as medicines, since they have lacked any useful activity when administered orally at pharmaceutically acceptable doses. Although it is known that a number of factors influence oral bioavailability, the design of enzyme inhibitors with high oral bioavailability is far from straightforward. Finding a combination of R₁, R₂, R₃, R₄, or R₅ substituents that permits a good balance of intrinsic level of activity, water solubility, oral absorption, and pharmacokinetic properties is a continuing problem in the art, since those properties can vary in an unpredictable way as the substituents R₁- R₅ are varied. Identifying hydroxamic acid and carboxylic acid based MMP inhibitors having such properties remains a much sought after goal in the art.

Now we have found novel potent hydroxamic acid and carboxylic acid thioamide derivatives that have advantageously good oral bioavailability, and after oral administration have advantageously longer duration of action and a pharmacokinetically better profile than their structurally closely related analogues.

This invention thus relates to a hitherto unknown class of compounds of formula (I) below wherein X is a hydroxamic acid or a carboxylic acid group characterised primarily in that one or both Y and Z groups are the atom S.

The present invention provides compounds of general formula (I)



wherein

X is a $-CO_2H$ or $-CONHOH$ group;

Y and Z are independently sulphur or oxygen, at least one being sulphur

R_1 is hydrogen, hydroxy, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_3-C_8) cycloalkyl;

R_2 is a (C_1-C_{24}) alkyl, phenyl (C_1-C_6) alkyl, or phenyl (C_0-C_6) alkyl $O(C_1-C_6)$ alkyl, any of which may be optionally substituted by (C_1-C_6) alkyl, (C_1-C_6) alkoxy, halo, or cyano (CN);

R_3 is the characterising side chain of a natural α -amino acid in which any functional groups may be protected, (C_1-C_6) alkyl which may be optionally substituted, or cycloalkyl (C_1-C_6) alkyl;

R_4 is hydrogen, (C_1-C_6) alkyl, phenyl (C_1-C_6) alkyl, optionally substituted phenyl or heteroaryl, or a group of formula $-(Q-O)_n-Q$ where Q is a straight or branched (C_1-C_6) alkyl, where n is an integer >1 and no continuous linear sequence of atoms in the group R_4 is >12 ; any of the above alkyl or alkenyl groups being straight or branched;

or a salt, hydrate or solvate thereof.

As used in the specification, unless specified to the contrary, the following terms have the meaning indicated:

“Alkyl” refers to a straight or branched chain alkyl moiety, consisting solely of carbon and hydrogen, containing no unsaturation and having the number of carbon atoms specified, including for example methyl, n-propyl, isobutyl, t-butyl, hexyl and dodecyl.

“(C₂-C₆)alkenyl” refers to a straight or branched chain alkenyl moiety having 2 to 6 carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. This term would include, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl.

“Alkoxy” refers to a radical of the formula -OR, where R is alkyl as defined above, for example methoxy, n-propoxy, t-butoxy and the like.

“Cycloalkyl” means a saturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclopentyl, cyclohexyl, and cyclooctyl.

“Characterising side chain of a natural α -amino acid” means the characteristic side chain attached to the -CH(NH₂)(COOH) moiety in the following amino acids: alanine, arginine, aspartic acid, cysteine, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophane, tyrosine, valine. The amino acid side chains may be protected.

Unless otherwise specified in the context in which it occurs, the term “substituted” as applied to any moiety herein means substituted with up to four substituents, each of which independently may be a (C₁-C₆)alkoxy, hydroxy, thio, (C₁-C₆)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), cyano, trifluoromethyl, nitro, -COOH, -CONH₂, -CONHR^A or -CONR^AR^A wherein R^A is a (C₁-C₆)alkyl group or the residue of a natural α -amino acid.

Salts of the compounds of the invention can be formed with bases. Such salts include salts derived from inorganic or organic bases, for example metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium

salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

If the compounds of the invention contain basic moieties, salts may also be formed with pharmaceutically acceptable inorganic or organic acids, such as hydrochloric, hydrobromic, and hydroiodic acid, phosphoric acid, sulphuric acid, nitric acid, p-toluenesulphonic acid, methanesulphonic acid, formic acid, acetic acid, propionic acid, citric acid, tartaric acid, succinic acid, benzoic acid, maleic acid, these examples being considered as non-limiting for the invention.

There are several chiral centres in the compounds according to the invention because of the presence of asymmetric carbon atoms. The presence of several asymmetric carbon atoms gives rise to a number of diastereoisomers with R or S stereochemistry at each chiral centre. General formula (I), and (unless specified otherwise) all other formulae in this specification are to be understood to include all such stereoisomers and mixtures (for example racemic mixtures).

In the compounds of the invention, the preferred stereochemistry is in general as follows:

C atom carrying the R₁ and X groups -(S),

C atom carrying the R₂ group -(R),

C atom carrying the R₃ group -(S),

but mixtures in which the above configurations predominate are also contemplated. Without limiting the generality of the foregoing:

Preferred compounds of formula I are those in which X represents - CONHOH.

Examples of particular R₁ groups include hydrogen, hydroxy, methyl, ethyl, n-propyl, allyl and methoxy. Presently preferred are compounds in which R₁ is hydrogen, hydroxyl, allyl or propyl.

Examples of particular R₂ groups include (C₄-C₂₄)alkyl, phenyl(C₁-C₆)alkyl. Presently preferred are compounds in which R₂ is isobutyl, phenylpropyl, (4-chlorophenyl)propyl, (4-methylphenoxy)ethyl or (C₆-C₁₆)alkyl.

Examples of particular R₃ groups include benzyl, 4-methoxybenzyl, isobutyl, t-butyl, cyclohexylmethyl, indolmethyl, 1-fluoromethylethyl, isopropyl. Presently

preferred are compounds in which R₃ is benzyl, t-butyl, cyclohexylmethyl, 4-methoxybenzyl, indolmethyl, isobutyl or isopropyl.

Examples of particular R₄ groups include (C₁-C₆)alkyl, phenyl(C₁-C₆)alkyl and a polyether chain possessing at least two non-adjacent oxygen atoms. Presently
5 preferred are compounds in which R₄ is methyl, phenylpropyl, 2-(2-methoxyethoxy)ethyl, 2-(2-methoxyethoxymethoxy)ethyl or 2-(ethoxyethoxymethoxy)ethyl.

Examples of the invention are:

10 *N*⁴-Hydroxy-2(R)-phenylethyl-*N*¹-[1(S)-(3-phenylpropylthiocarbamoyl)-2-phenylethyl]-succinamide

*N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-[1(S)-(3-phenylpropylthiocarbamoyl)-2-phenylethyl]-succinamide

15 *N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-[1(S)-(methylthiocarbamoyl)-2-phenylethyl]-succinamide

*N*⁴-Hydroxy-*N*¹-[1(S)-(methylthiocarbamoyl)-2-phenylethyl]-2(R)-phenylpropyl-succinamide
20

*N*⁴-Hydroxy-2(R)-phenylpropyl-*N*¹-[1(S)-(3-phenylpropylthiocarbamoyl)-2-phenylethyl]-succinamide

25 *N*⁴-Hydroxy-2(R)-phenylpropyl-*N*¹-[1(S)-(3-phenylpropylthiocarbamoyl)-2-cyclohexylethyl]-succinamide

*N*⁴-Hydroxy-*N*¹-[1(S)-(methylthiocarbamoyl)-2-cyclohexylethyl]-2(R)-phenylpropyl-succinamide
30

*N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-thiono-*N*¹-[1(S)-(methylcarbamoyl)-2-phenylethyl]-succinamide

5 3(S), *N*⁴-Dihydroxy-2(R)-isobutyl-*N*¹-[1(S)-(methylthiocarbamoyl)-2-cyclohexylethyl]-succinamide

3(S), *N*⁴-Dihydroxy-2(R)-isobutyl-*N*¹-[1(S)-(methylthiocarbamoyl)-2-phenylethyl]-succinamide

10 *N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-[1(S)-(3-phenylpropylthiocarbamoyl)-2-cyclohexylethyl]-succinamide

*N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-[1(S)-(3-methylthiocarbamoyl)-2-cyclohexylethyl]-succinamide

15 *N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-[1(S)-(3-methylthiocarbamoyl)-2-(1*H*-indol-3-yl)ethyl]-succinamide

*N*⁴-Hydroxy-*N*¹-{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-phenylethyl}-2(R)-phenylpropyl-succinamide

20 3(S), *N*⁴-Dihydroxy-2(R)-isobutyl-*N*¹-[1(S)-(methylthiocarbamoyl)-2,2-dimethyl-propyl]-succinamide

25 3(S)-Allyl-*N*⁴-hydroxy-2(R)-isobutyl-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2,2-dimethyl-propyl}-succinamide

30 3(S)-Allyl-*N*⁴-hydroxy-2(R)-isobutyl-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)ethyl}-succinamide

*N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-[1(S)-(methylthiocarbamoyl)-2-methyl-propyl]-3(S)-propyl-succinamide

5 *N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-3-methyl-butyl)-3(S)-propyl-succinamide

2(R)-Dodecyl-*N*⁴-hydroxy-*N*¹-[1(S)-(methylthiocarbamoyl)-3-methyl-butyl]-succinamide

10 2(R)-Dodecyl-*N*⁴-hydroxy-*N*¹-[1(S)-(phenylethylthiocarbamoyl)-2-methyl-butyl]-succinamide

2(R)-Hexadecyl-*N*⁴-hydroxy-*N*¹-[1(S)-(phenylthiocarbamoyl)-ethyl]-succinamide

15 2(R)-Hexadecyl-*N*⁴-hydroxy-*N*¹-[1(S)-(methylthiocarbamoyl)-2,2-dimethyl-propyl]-succinamide

20 3(S), *N*⁴-Dihydroxy-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)-ethyl}-2(R)-phenylpropyl-succinamide

3(S), *N*⁴-Dihydroxy-*N*¹-{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-2(R)-phenylpropyl-succinamide

25 *N*⁴-Hydroxy-2(R)-(4-chlorophenyl)propyl-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)ethyl}-succinamide

*N*⁴-Hydroxy-2(R)-(4-chlorophenyl)propyl-*N*¹-(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-3-methyl-butyl)-succinamide

30

N^4 -Hydroxy-2(R)-(4-chlorophenyl)propyl- N' -{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-succinamide

5 N^4 -Hydroxy-2(R)-(4-chlorophenyl)propyl- N' -[1(S)-(methylthiocarbamoyl)-2-(1*H*-indol-3-yl)ethyl]-succinamide

N^4 -Hydroxy- N' -{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-2(R)-(4-methylphenoxy)ethyl-succinamide

10 N^4 -Hydroxy- N' -(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-(4-methoxyphenyl)ethyl)-2(R)-(4-methylphenoxy)ethyl-succinamide

15 N^4 -Hydroxy- N' -[1(S)-(methylthiocarbamoyl)-2-(1*H*-indol-3-yl)ethyl]-2(R)-(4-methylphenoxy)ethyl-succinamide

Examples of prior art patent publications are given below:

20 EP-A-0214639(Searle)
EP-A-0489577(Celltech)
WO 96/16931 (British Biotech)
WO 96/33991 (Sankyo)

25 The general formula (A) of the prior art patent publications depicts simple peptidic compounds as compared to the thiopeptides of general formula (I) of the present invention. It has now surprisingly been found that not only do the compounds of the present invention have enhanced stability toward enzymatic degradation as compared to that of their oxygenated counterpart, but are also more potent inhibitors than compounds of the prior art publications.

The compounds were tested *in vitro* using the following procedure: matrix metalloproteinases were obtained from culture media conditioned by MCF-7 human breast cancer cells and separated by electrophoresis on SDS-acrylamide gels (7.0%) copolymerised with gelatine (1mg/ml, Sigma, MO, USA). The gels containing the MMPs were then incubated with the test compounds overnight in 10 ml buffer (50 mM tris-HCl, pH 7.5, 200mM NaCl, 5 mM CaCl₂, 1 μ M ZnCl₂, 0.002% NaN₃) at 37°C. The gels were stained for 60 min with 0.5% Coomassie brilliant blue R-250 in 10% acetic acid, destained with 10% acetic acid, incubated with 5% glycerol, and dried with a gel drier. The molar concentrations that inhibited approximately half of the maximal enzymatic activity were then determined. The results for some of the compounds of the invention and a comparator compound selected from one of the prior art publications listed above (EP-A-0214639) are shown in Table 1.

Table 1. Inhibition of MMPs 2/3 and 9 *in vitro* by compounds of the following examples of the present invention and comparators.


Compound	<i>In vitro</i> inhibition of matrix metalloproteinases (nM)	
	MMP-2/3	MMP-9
Example 3	1×10^{-9}	1×10^{-9}
Example 4	1×10^{-9}	1×10^{-9}
Example 5	1×10^{-9}	1×10^{-9}
Comparator 1	1×10^{-8}	1×10^{-8}

Comparator 1: N¹-Hydroxy-3R-isobutyl- N⁴-[1S-(methylcarbamoyl)-2-phenylethyl]-succinamide (EP-A 0214639).

The compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of organic synthesis. The compounds of the present invention can be synthesised using the methods outlined below, together with methods known in the art of synthetic organic chemistry, or variations thereof as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.

The novel compounds of formula (I) may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of experiment and work-up procedures, are chosen to be conditions of standard for that reaction, which should be readily recognised by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the educt molecule must be compatible with the reagents and reactions proposed. Not all compounds of formula (I) falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods can be used.

Compounds according to the present invention in which X is a hydroxamic acid group -CONHOH may be prepared from compounds of the invention in which X is a carboxylic acid group -COOH. That process, which forms another aspect of the invention, comprises reacting an acid of general formula (II)



20

with hydroxylamine, O-protected hydroxylamine, N,O-diprotected hydroxylamine. The acids (II) may themselves be protected from such reaction, then removing any protecting groups from the resulting hydroxamic acid moiety and from any protected substituents in R₁, R₂, R₃, and R₄.


25

The condensation is carried out using any of the many methods for the formation of amide bonds known to one skilled in the art of organic synthesis. These

methods include, but are not limited to, use of standard coupling procedures such as mixed carbonic anhydride (isobutyl chloroformate) method, carbodiimide (N,N-dimethylaminopropyl-N'-ethyl carbodiimide (EDC), dicyclohexyl carbodiimide, diisopropyl carbodiimide) method, active ester (pentafluorophenyl ester, p-nitrophenyl ester, N-hydroxysuccinic imido ester) method, carbonyldiimidazole method, azide method, phosphorous reagents such as BOP-Cl, azide method, conversion of acid (II) to an acid chloride. Some of these methods (especially carbodiimide) can be enhanced by the addition of 1-hydroxybenzotriazole (HOBt).

Protecting groups as referred to above are well known *per se*, for example from the techniques of peptide chemistry. Amino groups can often be protected by *tert*-butoxycarbonyl, benzyloxycarbonyl or acetyl groups, or in the form of a phthalimido group. Hydroxy groups are often protected as readily cleavable ethers such as the *t*-butyl or benzyl ether, or as readily cleavable esters such as the acetate. Carboxylic acid groups are often protected as readily cleavable esters such as the *t*-butyl or benzyl ester.


In the special case where R_1 in compound (I) is hydroxy, it too may be protected during the coupling of compounds (II). In that case a particularly useful technique may be simultaneous protection of the hydroxy group R_1 and the adjacent carboxyl group as a dioxalone of formula (IIa):




wherein the groups R_5 and R_6 are derived from a dioxalone forming reagent, and may be, for example, hydrogen, alkyl, phenyl or substituted phenyl. The dioxalone ring is opened on reaction with hydroxylamine to give the required hydroxamic acid derivative of formula (I).

Compounds according to the invention in which X is a carboxylic acid group -COOH, Y is oxygen and Z is sulphur may be prepared by a process comprising: coupling of an acid of formula (III) or an activated derivative thereof with an amine of formula (IV), as shown in Scheme 1, where R is an ester protecting group, and R₁,
5 R₂, R₃, and R₄ are as defined in general formula (I), except that any substituents in R₁, R₂, R₃, and R₄ which are potentially reactive in the coupling reaction may themselves be protected from such reaction and the protecting groups subsequently removed. The condensation is carried out using any of the many methods for the formation of amide bonds, as described above.

10




In the special case where R_1 in compound (III) is hydroxy, it too may be protected during the coupling of compounds (III) and (IV). In that case a particularly useful technique may be simultaneous protection of the hydroxy and carboxy groups as a dioxalane of formula (VII), as described above for compounds of general
5 formula (IIa):



The amines of formula (IV) are prepared from the corresponding α -amino
10 acids by methods described in the literature (M. A. Shalaby, C. W. Grote, H. Rapoport; *J. Org. Chem* (1996) **61** 9045-48) and as outlined in Scheme 2 below, in which R is an amine protecting group in the form of a carbamate, for example t-butyl or benzyl.

Starting materials (III) and the α -amino acid starting materials referred to
15 above are either known compounds or prepared by routine known synthetic methods, for example as in the relevant patent publications listed above.


SCHEME2



- Compounds according to the invention in which X is a carboxylic acid group $-COOH$, Y is oxygen and Z is oxygen or sulphur may be prepared by a process comprising: conversion of starting material (III) into an activated species (XIV), which is then allowed to react with amine (XV), as shown in Scheme 3 below.

The present compounds are intended for use in pharmaceutical compositions which are useful in the treatment of the above mentioned diseases.

SCHEME 3



The amount required of a compound of formula I (hereinafter referred to as the active ingredient) for therapeutic effect will, of course, vary both with the particular compound, the route of administration and the mammal under treatment. A suitable dose of a compound of formula I for systemic treatment is 0.1 to 200 mg/kg bodyweight, the most preferred dosage being 0.2 to 50 mg/kg of mammal bodyweight, administered one or more times daily.

While it is possible for an active ingredient, such as a compound according to this invention, to be administered alone as the raw chemical, it is preferable to

administer a compound of the invention as a pharmaceutical formulation.

Conveniently, the active ingredient comprises from 0.1% to 100% by weight of the formulation. Conveniently, dosage units of a formulation contain between 0.07 mg and 1 g of the active ingredient, preferably from about 0.5 mg to about 500 mg of the active ingredient, more preferably about 50 mg, e.g. for oral administration. For 5 topical administration, the active ingredient preferably comprises from 1% to 20% by weight of the formulation but the active ingredient may comprise as much as 50% w/w. Formulations suitable for nasal or buccal administration may comprise 0.1% to 20% w/w. for example about 2% w/w of active ingredient.

10 By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.

15 The formulations, both for veterinary and human medical use, of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredient(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.

20 The formulations include those in a form suitable for oral, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular and intravenous), transdermal, intra-articular, topical, nasal, or buccal administration.

The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods 25 include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

30 Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing

a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. The active ingredient may also be administered in the form of a bolus, electuary or paste.

- 5 Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and a carrier such as cocoa butter, or in the form of an enema.

- Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably
10 isotonic with the blood of the recipient.

- Formulations suitable for intra-articular administration may be in the form of a sterile aqueous preparation of the active ingredient which may be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems may also be used to
15 present the active ingredient for both intra articular and ophthalmic administration.

 Formulations suitable for topical administration, including eye treatment, include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops.

- 20 Formulations suitable for administration to the nose or buccal cavity include powder, self-propelling and spray formulations, such as aerosols and atomisers.

 In addition to the aforementioned ingredients, the formulations of this invention may include one or more additional ingredients.

- The compositions may further contain other therapeutically active compounds
25 usually applied in the treatment.

 The invention is further illustrated by the following general procedures, preparations and examples.


General Procedures, Preparations and Examples

The exemplified compounds are listed in Table 6, compounds of general formula (II) in Table 5, intermediates of general formula (X) in Table 2, intermediates of general formula (IV) in Table 3, and intermediates of general formula (IIa) are listed in Table 4. Compounds of general formula (II) are found in the preparations, not in the examples.


All melting points are uncorrected. For ^1H nuclear magnetic resonance (NMR) spectra (300 MHz) and ^{13}C NMR (75.6 MHz) chemical shift values (δ) (in ppm) are quoted, unless otherwise specified, for deuteriochloroform solutions relative to internal tetramethylsilane ($\delta = 0.00$) or chloroform ($\delta = 7.25$) or deuteriochloroform ($\delta = 76.81$ for ^{13}C NMR). The value of a multiplet, either defined (doublet (d), triplet (t), quartet (q)) or not (m) at the approximate mid point is given unless a range is quoted. Mass spectra were recorded on a QUATTRO II (micro-mass). The organic solvents used were anhydrous. Chromatography was performed on silica gel.

The following abbreviations have been used throughout:


BOC	<i>tert</i> -Butyloxycarbonyl
DMF	<i>N,N</i> -Dimethylformamide
EDC	<i>N</i> -Ethyl- <i>N'</i> -(3-dimethylaminopropyl)carbodiimide
hydrochloride	
HOBt	1-Hydroxybenzotriazole
^iBu	Isobutyl
Me	Methyl
MS	Mass spectroscopy
NMM	<i>N</i> -methylmorpholine
NMR	Nuclear magnetic resonance
RT	Room temperature
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran

Table 2 Some compounds of general formula (X)


Compound No.	Preparation No.	R	R ₃
201	1	<i>tert</i> -butyl	phenylmethyl
202	2	<i>tert</i> -butyl	cyclohexylmethyl
203	3	<i>tert</i> -butyl	<i>tert</i> -butyl

Table 3 Some compounds of general formula (IV)

Compound No.	Preparation No.	R ₃	R ₄
205	5	phenylmethyl	methyl
206	6	phenylmethyl	3-phenylpropyl
207	7	cyclohexylmethyl	methyl
208	8	cyclohexylmethyl	3-phenylpropyl

5 **Table 4** Some compounds of general formula (IIa)

Comp No.	Prep. No.	R ₂	R ₃	R ₄	R ₅ = R ₆	Y	Z
217	17	isobutyl	cyclohexylmethyl	methyl	methyl	O	S
218	18	isobutyl	phenylmethyl	methyl	methyl	O	S
223	23	isobutyl	<i>tert</i> -butyl	methyl	methyl	O	S
232	32	phenylpropyl (4-MeO)-	phenylmethyl		methyl	O	S
233	33	phenylpropyl isopropyl			methyl	O	S

Table 5 Compounds of general formula (II)

Comp No.	Prep. No.	R ₁	R ₂	R ₃	R ₄	Y	Z
209	9	H	2-phenylethyl	phenylmethyl	3-phenylpropyl	O	S
210	10	H	isobutyl	phenylmethyl	3-phenylpropyl	O	S
211	11	H	isobutyl	phenylmethyl	methyl	O	S
212	12	H	3-phenylpropyl	phenylmethyl	methyl	O	S
213	13	H	3-phenylpropyl	phenylmethyl	3-phenylpropyl	O	S
214	14	H	3-phenylpropyl	cyclohexylmethyl	3-phenylpropyl	O	S
215	15	H	3-phenylpropyl	cyclohexylmethyl	methyl	O	S
216	16	H	isobutyl	phenylmethyl	methyl	S	O
219	19	H	Isobutyl	cyclohexylmethyl	3-phenylpropyl	O	S
220	20	H	isobutyl	cyclohexylmethyl	methyl	O	S
221	21	H	isobutyl	indolmethyl	methyl	O	S
222	22	H	3-phenylpropyl	phenylmethyl		O	S
224	24	allyl	isobutyl	<i>tert</i> -butyl		O	S
225	25	allyl	isobutyl	4-methoxy-phenylmethyl		O	S
226	26	propyl	isobutyl	isopropyl	methyl	O	S
227	27	propyl	isobutyl	isobutyl		O	S
228	28	H	dodecyl	isobutyl	methyl	O	S
229	29	H	dodecyl	2-butyl	phenylethyl	O	S
230	30	H	hexadecyl	methyl	phenyl	O	S
231	31	H	hexadecyl	<i>tert</i> -butyl	methyl	O	S
234	34	H	3-(4-Cl-phenyl)4-methoxy-propyl	phenylmethyl		O	S
235	35	H	3-(4-Cl-phenyl)isobutyl	propyl		O	S
236	36	H	3-(4-Cl-phenyl)isopropyl	propyl		O	S

















237	37	H	3-(4-Cl-phenyl) propyl	indolmethyl	methyl		O S
238	38	H	2-(4-Me-phenoxy)ethyl	isopropyl		O S	
239	39	H	2-(4-Me-phenoxy)ethyl	4-methoxy-phenylmethyl		O S	
240	40	H	2-(4-Me-phenoxy)ethyl	indolmethyl	methyl		O S

Table 6 Exemplified compounds



Comp No.	Ex. No.	R ₁	R ₂	R ₃	R ₄	Y	Z
101	1	H	2-phenylethyl	phenylmethyl	3-phenylpropyl	O	S
102	2	H	isobutyl	phenylmethyl	3-phenylpropyl	O	S
103	3	H	isobutyl	phenylmethyl	methyl	O	S
104	4	H	3-phenylpropyl	phenylmethyl	methyl	O	S
105	5	H	3-phenylpropyl	phenylmethyl	3-phenylpropyl	O	S
106	6	H	3-phenylpropyl	cyclohexylmethyl	3-phenylpropyl	O	S
107	7	H	3-phenylpropyl	cyclohexylmethyl	methyl	O	S
108	8	H	isobutyl	phenylmethyl	methyl	S	O
109	9	OH	isobutyl	cyclohexylmethyl	methyl	O	S
110	10	OH	isobutyl	phenylmethyl	methyl	O	S
111	11	H	Isobutyl	cyclohexylmethyl	3-phenylpropyl	O	S
112	12	H	isobutyl	cyclohexylmethyl	methyl	O	S
113	13	H	isobutyl	indolmethyl	methyl	O	S
114	14	H	3-phenylpropyl	phenylmethyl		O	S
115	15	OH	isobutyl	<i>tert</i> -butyl	methyl	O	S
116	16	allyl	isobutyl	<i>tert</i> -butyl		O	S
117	17	allyl	isobutyl	4-methoxy-		O	S
118	18	propyl	isobutyl	isopropyl	methyl	O	S
119	19	propyl	isobutyl	isobutyl		O	S
120	20	H	dodecyl	isobutyl	methyl	O	S
121	21	H	dodecyl	2-butyl	phenylethyl	O	S
122	22	H	hexadecyl	methyl	phenyl	O	S
123	23	H	hexadecyl	<i>tert</i> -butyl	methyl	O	S
124	24	OH	3-phenylproyl	4-methoxy-		O	S
125	25	OH	3-phenylpropyl	isopropyl		O	S

126	26	H	3-(4-Cl-phenyl)	4-methoxy-		O S
127	27	H	3-(4-Cl-phenyl)	isobutyl		O S
128	28	H	3-(4-Cl-phenyl)	isopropyl		O S
129	29	H	3-(4-Cl-phenyl)	indolmethyl	methyl	O S
			propyl			
130	30	H	2-(4-Me-phenoxy)ethyl	isopropyl		O S
131	31	H	2-(4-Me-phenoxy)ethyl	4-methoxy-phenylmethyl		O S
132	32	H	2-(4-Me-phenoxy)ethyl	indolmethyl	methyl	O S

General Procedure 1: Formation of thioacylating reagents of general formula (X) (cf. Scheme 2).

(M. A. Shalaby, C. W. Grote, H. Rapoport; *J. Org. Chem* (1996) **61** 9045-48).

- 5 NMM (2.2 ml; 20 mmol) was added to a solution of the N^α -BOC amino acid in THF at -20 °C, followed by dropwise addition of isobutyl chloroformate (1.3 ml, 10 mmol). The mixture was stirred for 30 min, 4-nitro-1,2-phenylenediamine (1.53 g, 10 mmol) was added, and the resulting slurry was stirred at -15 °C for 2h and at RT overnight. The mixture was filtered through Celite and the filtrate concentrated. The
- 10 residue was dissolved in EtOAc, and the solution was washed successively with 1 M NaHPO₄, brine, 5% NaHCO₃, and brine, then dried (MgSO₄) and concentrated. The residue was purified either by crystallisation (EtOAc/ petroleum ether) or chromatography (EtOAc/ petroleum ether) to afford the anilide (VIII).

- Under a flow of argon, P₄S₁₀ (1.1 g, 2.5 mmol) was mixed with
- 15 Na₂CO₃ (0.27 g, 2.5 mmol) in THF (100 ml). The mixture was stirred for 1h at RT and then cooled to 0 °C. To this solution was added anilide (VIII) (5 mmol), and the reaction mixture was stirred at 0 °C for 30 min and at RT for 2.5 h. The mixture was filtered through Celite and the filtrate was evaporated. The residue was dissolved in EtOAc and washed twice with 5% NaHCO₃, and the aqueous layers were back-
 - 20 extracted with EtOAc. The combined organic layers were washed with brine, dried (MgSO₄) and concentrated. The residue was purified by chromatography (EtOAc/ petroleum ether) to afford the thioanilide (IX). To a solution of thioanilide (IX) (2 mmol) in glacial acetic acid (diluted with 5% water, 15 ml) was added NaNO₃ (0.21 g, 3 mmol) in portions over 5 min with stirring. After 30 min, ice water (~100 ml)

was added, and the precipitated product was filtered and washed with water. The solid was dried *in vacuo* overnight and then at 50 °C for 4 h to afford thioacylating reagent (X).

5 General Procedure 2: Formation of amines of general formula (IV) (cf. Scheme 2).

To a cooled (0 °C) solution of thioacylating reagent (X) (2 mmol) in 30 ml THF was added dropwise a solution of amine R_4NH_2 (2 mmol) in 10 ml THF over a period of 15 min. After 1 h the solvent was evaporated and the residue purified by
10 chromatography (EtOAc/ petroleum ether) to afford the protected amine (XI).

To a solution of protected amine (XI) in CH_2Cl_2 (4 ml) was added dropwise with stirring 4 ml Et_2O saturated with HCl. After 1 h 20 min the precipitated product was filtered off and washed with Et_2O , to yield amine of general formula (IV) as a hydrochloric acid salt.

15 Alternatively, protected amine (XI) (2 mmol) was dissolved in TFA (20 ml). After 50 min at RT the solution was concentrated, evaporated twice with toluene and once with methanol, to afford amine of general formula (IV) as a trifluoroacetic acid salt.

20 General Procedure 3: Coupling of acids of general formula (III) with amines of general formula (IV) and subsequent ester hydrolysis (cf. Scheme 1).

To a solution of acid with the general formula (III) (3.4 mmol), amine of general formula (IV) (3.4 mmol, as a hydrochloric or trifluoroacetic acid salt), HOBt (3.4 mmol) and NMM (10.2 mmol) in DMF (20 ml) was added EDC (4.4 mmol)
25 with stirring. The mixture was left at RT overnight and extracted with EtOAc/ H_2O . The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with 2N NaOH, H_2O , 1N HCl, H_2O , brine, dried ($MgSO_4$) and concentrated. The residue was purified by chromatography (EtOAc/ petroleum ether) to afford the ester of general formula (V). Ester of general formula (V) (2.9 mmol)
30 was subsequently dissolved in formic acid (50 ml) and was left at RT for 1h 20 min,

concentrated, concentrated twice with toluene and once with methanol, to yield acid of general formula (VI).

5 General Procedure 4: Coupling of acids of general formula (VII) with amines of general formula (IV).

Acid of general formula (VII) (2.4 mmol) was dissolved in CH_2Cl_2 (10 ml) and cooled to 0°C before adding pentafluorophenol (670 mg, 3.6 mmol) and EDC. (560 mg, 2.9 mmol). The reaction mixture was stirred at 0°C for 2h then the solution was washed with 1N Na_2CO_3 and brine. The organic layer was dried (MgSO_4) and
10 concentrated. The residue was purified by chromatography (CH_2Cl_2) to give a pentafluorophenyl ester.

The pentafluorophenyl ester (2.0 mmol) was dissolved in DMF (2 ml) and cooled to 0°C before adding amine of general formula (IV) (1.95 mmol). The solution was stirred at 0°C for 10 min, then overnight at RT. The solvent was
15 evaporated and the residue was dissolved in Et_2O and washed successively with H_2O , 1N Na_2CO_3 , H_2O , brine, dried (MgSO_4) and concentrated. The residue was purified either by crystallisation or chromatography to afford a compound of general formula (IIa).

20 General Procedure 5: Formation of thioacylating reagents of general formula (XIV) (cf. Scheme 3).

Thioacylating reagents of general formula (XIV) were formed analogously to thioacylating reagent (X), see General Procedure 1, starting from carboxylic acids of general formula (III).

25

General Procedure 6: Formation of carboxylic acids of general formula (XVII) (cf. Scheme 3).

To a cooled (0°C) solution of thioacylating reagent (XIV) (2 mmol) in 30 ml THF was added dropwise a solution of amine (XV) (2 mmol) in 10 ml THF over a
30 period of 15 min. After 1 h the solvent was evaporated and the residue purified by

chromatography (EtOAc/ petroleum ether) to afford the ester of general formula (XVI).

Ester of general formula (XVI) (1.6 mmol) was dissolved in TFA and left at RT for 15 min. The solution was then concentrated, concentrated twice with toluene, once with methanol and purified by chromatography (1-5% methanol in CH₂Cl₂) to yield carboxylic acid of general formula (XVII).

General Procedure 7: Formation of hydroxamic acids of general formula (I) from the corresponding carboxylic acids of general formula (II) or (XVII).

A solution of carboxylic acid with general formula (II) (2.9 mmol) in THF (45 ml) was cooled to -10 °C under argon. NMM (0.3 ml, 3.0 mmol) and isobutyl chloroformate (0.4 ml, 3.0 mmol) were then added with stirring. After 30 min at -10 °C, *O*-trimethylsilyl hydroxylamine (0.4 ml, 3.2 mmol) was added, and the mixture was left at -10 °C for 2h. The mixture was then acidified with 1N acetic acid, extracted with EtOAc/H₂O. The aqueous layer was back-extracted with EtOAc, and the combined organic layers were washed with H₂O, brine, dried (MgSO₄) and evaporated. The residue was purified by chromatography (chloroform: methanol: NH₃ (25%) 95:5:1) or crystallisation to afford the hydroxamic acid of general formula (I).

General Procedure 8: Formation of hydroxamic acids of general formula (I) from the corresponding compounds of general formula (IIa):

To a solution of compound of general formula (IIa) (0.1 mmol) in dichloromethane (2 ml) was added *O*-trimethylsilyl hydroxylamine (0.037 ml, 0.3 mmol). The solution was left overnight and concentrated. The residue was purified by chromatography (chloroform: methanol: NH₃ (25%) 95:5:1) or crystallisation to afford the hydroxamic acid of general formula (I).

General Procedure 9: Formation of hydroxamic acids of general formula (I) from the corresponding carboxylic acids of general formula (II) or (XVII).

To a solution of carboxylic acid of general formula (II) (0.29 mmol) in dry DMF (4.5 ml) was added HOBt (0.38 mmol), NMM (0.38 mmol) and EDC (0.38 mmol). The reaction mixture was cooled to 0 °C and hydroxylamine hydrochloride (0.58 mmol) and NMM (0.58 mmol) were added. The reaction mixture was allowed to warm to room temperature and stirred overnight. After addition of ethyl acetate and water, the aqueous phase was separated and washed 3 times with ethyl acetate. The combined organic layers were washed with water and brine, dried and concentrated under reduced pressure. Flash chromatography (chloroform: methanol: NH₃ (25%) 95:5:1) afforded the hydroxamic acid of general formula (I).

10

Preparation 1: 1-(*N*^α-BOC-L-thionophenylalanine)-6-nitrobenzotriazole (compound 201).

General procedure 1.

Starting material: *N*^α-BOC-L-phenylalanine.

15 ¹³C NMR (CDCl₃) δ 209.0, 155.0, 149.5, 149.0, 135.3, 131.7, 129.4, 128.5, 127.3, 122.2, 121.5, 112.7, 80.5, 62.0, 42.8, 28.3.

Preparation 2: 1-(*N*^α-BOC-L-thionocyclohexylalanine)-6-nitrobenzotriazole (compound 202).

20 General procedure 1.

Starting material: *N*^α-BOC-L-cyclohexylalanine.

¹³C NMR (CDCl₃) δ 211.9, 155.5, 149.6, 149.0, 132.0, 122.1, 121.4, 112.9, 80.5, 59.7, 44.6, 35.0, 34.1, 32.0, 28.4, 26.4, 26.2, 25.9.

25 Preparation 3: 1-(*N*^α-BOC-L-thiono-*tert*-leucine)-6-nitrobenzotriazole (compound 203).

General procedure 1.

Starting material: *N*^α-BOC-L-*tert*-leucine.

30 ¹³C NMR (CDCl₃) δ 210.4, 155.5, 149.6, 149.4, 131.4, 122.2, 121.6, 112.9, 80.4, 66.3, 37.1, 28.4, 26.6.

Preparation 4: 1-[2(R)-isobutyl]-1-thionosuccinic acid 4-*tert*-butyl ester]-6-nitrobenzotriazole (compound 204).

General procedure 5.

5 Starting material: 2(R)-isobutyl-succinic acid 4-*tert*-butyl ester.

^{13}C NMR (CDCl_3) δ 215.6, 170.7, 149.4, 149.4, 131.9, 121.9, 121.3, 113.3, 81.1, 47.6, 46.6, 41.3, 28.0, 26.1, 23.0, 22.4.

Preparation 5: L-thionophenylalanine N-methylamide hydrochloric acid salt (compound 205).

General procedure 2.

Starting materials: compound 201 and methylamine.

^1H NMR (DMSO-d_6) δ 10.68(bs,1H), 8.46(bs,3H), 7.36-7.18(m,5H), 4.32(m,1H), 3.10(m,2H), 2.84(s,3H).

Preparation 6: L-thionophenylalanine N-(3-phenylpropyl)amide trifluoroacetic acid salt (compound 206).

General procedure 2.

Starting materials: compound 201 and 3-phenylpropylamine.

^{13}C NMR (DMSO-d_6) δ 196.8, 141.2, 134.7, 129.4, 128.4, 128.3, 128.2, 127.2, 125.9, 58.7, 44.6, 32.2, 28.2.

Preparation 7: L-thionocyclohexylalanine N-methylamide hydrochloric acid salt (compound 207).

General procedure 2.

Starting materials: compound 202 and 3-phenylpropylamine.

^{13}C NMR (DMSO-d_6) δ 198.9, 55.2, 41.3, 32.7, 32.6, 32.2, 31.9, 25.7, 25.4, 25.3.

Preparation 8: L-thionocyclohexylalanine N-(3-phenylpropyl)amide hydrochloride salt (compound 208).

General procedure 2.

Starting material: compound 202.

^{13}C NMR (DMSO-d_6) δ 198.3, 141.2, 128.2, 125.8, 55.3, 44.7, 41.3, 32.9, 32.8, 32.4, 32.0, 28.6, 25.7, 25.4, 25.4.

5

Preparation 9: 2(R)-phenylethyl-N-[1(S)-(3-phenylpropylthiocarbamoyl)-2-phenylethyl]-succinamic acid (compound 209).

General procedure 3.

Starting materials: 2(R)-phenylethyl-succinic acid 4-*tert*-butyl ester and
10 compound 206.

^{13}C NMR (CDCl_3) δ 201.7, 175.9, 174.2, 140.8, 140.8, 136.4, 129.3, 128.6, 128.5, 128.5, 128.4, 128.3, 127.1, 126.2, 126.1, 60.7, 45.3, 41.9, 41.8, 36.4, 33.8, 33.0, 33.0, 28.9.

15

Preparation 10: 2(R)-isobutyl-N-[1(S)-(3-phenylpropylthiocarbamoyl)-2-phenylethyl]-succinamic acid (compound 210).

General procedure 3.

Starting materials: 2(R)-isobutyl-succinic acid 4-*tert*-butyl ester and
compound 206.

20 ^{13}C NMR (CDCl_3) δ 201.7, 175.6, 174.8, 140.9, 136.6, 129.3, 128.6, 128.5, 128.3, 127.1, 126.1, 60.7, 45.3, 41.8, 41.2, 40.7, 36.7, 33.0, 28.9, 25.6, 22.6, 22.3.

Preparation 11: 2(R)-isobutyl-N-[1(S)-(methylthiocarbamoyl)-2-phenylethyl]-succinamic acid (compound 211).

25

General procedure 3.

Starting materials: 2(R)-isobutyl-succinic acid 4-*tert*-butyl ester and
compound 205.

^{13}C NMR (CDCl_3) δ 202.7, 176.2, 174.8, 136.5, 129.2, 128.5, 127.0, 60.4, 41.9, 41.3, 40.7, 36.7, 32.4, 25.6, 22.6, 22.3.

30

Preparation 12: *N*-[1(*S*)-(methylthiocarbamoyl)-2-phenylethyl]-2(*R*)-phenylpropyl-succinamic acid (compound 212).

General procedure 3.

Starting materials: 2(*R*)-phenylpropyl-succinic acid 4-*tert*-butyl ester and
5 compound 205.

¹H NMR (CDCl₃) δ 7.75(bq,1H), 7.34-7.07(m,10H), 6.87(d,1H), 4.83(m,1H),
3.13(dd,1H), 3.01(dd,1H), 2.89(d,3H), 2.77-2.31(m,5H), 1.74-1.36(m,4H).

Preparation 13: 2(*R*)-phenylpropyl-*N*-[1(*S*)-(3-phenylpropylthiocarbamoyl)-2-phenylethyl]-succinamic acid (compound 213).

General procedure 3.

Starting materials: 2(*R*)-phenylpropyl-succinic acid 4-*tert*-butyl ester and
compound 206.

¹H NMR (CDCl₃) δ 7.38(bt,1H), 7.32-7.01(m,15H), 6.88(d,1H), 4.73(m,1H),
15 3.43(m,2H), 3.15(dd,1H), 2.98(dd,1H), 2.72-2.50(m,5H), 2.43(t,2H), 1.75-
1.40(m,6H).

Preparation 14: 2(*R*)-phenylpropyl-*N*-[1(*S*)-(3-phenylpropylthiocarbamoyl)-2-cyclohexylethyl]-succinamic acid (compound 214).

20 General procedure 3.

Starting materials: 2(*R*)-phenylpropyl-succinic acid 4-*tert*-butyl ester and
compound 208.

¹H NMR (CDCl₃) δ 8.42(t,1H), 7.36-7.06(m,10H), 6.46(d,1H), 4.66(m,1H),
3.73-3.44(m,2H), 2.79-2.49(m,6H), 2.42(dd,1H), 1.91(m,2H), 1.77-0.73(m,17H).

25

Preparation 15: *N*-[1(*S*)-(methylthiocarbamoyl)-2-cyclohexylethyl]-2(*R*)-phenylpropyl-succinamic acid (compound 215).

General procedure 3.

Starting materials: 2(*R*)-phenylpropyl-succinic acid 4-*tert*-butyl ester and
30 compound 207.

^1H NMR (CDCl_3) δ 8.84(q,1H), 7.32-7.09(m,5H), 6.48(d,1H), 4.77(m,1H), 2.99(d,3H), 2.73(dd,1H), 2.60(m,3H), 2.43(dd,1H), 1.77-0.75(m,17H).

5 Preparation 16: (R)-isobutyl-*N*-thiono- *N*-[1(S)-(methylcarbamoyl)-2-phenylethyl]-succinamic acid (compound 216).

General procedure 6.

Starting materials: compound 204 and L-phenylalanine *N*-methylamide.

^{13}C NMR (CDCl_3) δ 208.6, 177.1, 171.0, 136.5, 129.2, 128.7, 127.1, 60.5, 49.2, 44.1, 40.5, 37.2, 26.2, 25.5, 23.0, 22.1.

10

Preparation 17: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-4-methylpentanoic acid [1(S)-(methylthiocarbamoyl)-2-cyclohexylethyl]-amide (compound 217).

General procedure 4.

15 Starting materials: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-4-methylpentanoic acid and compound 207.

^{13}C NMR (CDCl_3) δ 205.1, 172.0, 171.1, 111.0, 74.7, 56.6, 47.2, 42.9, 36.8, 34.1, 33.7, 32.6, 32.5, 26.9, 26.4, 26.4, 26.1, 25.8, 25.7, 23.4, 21.7.

20 Preparation 18: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-4-methylpentanoic acid [1(S)-(methylthiocarbamoyl)-2-phenylethyl]-amide (compound 218).

General procedure 4.

25 Starting materials: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-4-methylpentanoic acid and compound 205.

^{13}C NMR (CDCl_3) δ 202.6, 172.2, 170.5, 136.6, 129.1, 128.7, 127.1, 111.2, 74.8, 60.7, 46.8, 41.5, 36.2, 32.5, 26.8, 25.8, 25.6, 23.3, 21.7.

30 Preparation 19: 2(R)-isobutyl-*N'*-[1(S)-(3-phenylpropylthiocarbamoyl)-2-cyclohexylethyl]-succinamic acid (compound 219).

General procedure 3.

Starting materials: 2(R)-isobutyl-succinic acid 4-*tert*-butyl ester and compound 208.

¹³C NMR (CDCl₃) δ 204.1, 176.1, 175.1, 141.0, 128.5, 128.4, 126.2, 57.0,
5 45.4, 42.8, 41.4, 40.6, 36.6, 34.1, 33.4, 33.3, 32.9, 29.3, 26.4, 26.2, 26.0, 25.6, 22.7,
22.3, 15.2.

Preparation 20: 2(R)-isobutyl-*N'*-[1(S)-(3-methylthiocarbamoyl)-2-cyclohexylethyl]-succinamic acid (compound 220).

10 General procedure 3.

Starting materials: 2(R)-isobutyl-succinic acid 4-*tert*-butyl ester and compound 207.

¹H NMR (CDCl₃) δ 8.70(d,1H), 6.60 (d,1H), 4.78 (q,1H, 3.08
(d,3H),3.10(m,1H), 2.7 (m,2H), 2.5 (m,1H), 1.7 (m,6H),1.2(m,10H), 0.93 (d,3H),
15 0.88 (d,3H).

Preparation 21: 2(R)-isobutyl-*N'*-[1(S)-(3-methylthiocarbamoyl)-2-(1*H*-indol-3-yl)ethyl]-succinamic acid (compound 221).

General procedure 3.

20 Starting materials: 2(R)-isobutyl-succinic acid 4-*tert*-butyl ester and L-thionotryptophane *N*-methanamide hydrochloric acid salt (prepared as described for compound 205).

¹³C NMR (CDCl₃) δ 203.2, 177.9, 176.4, 136.0, 127.4, 123.5, 122.1, 119.5,
118.6, 111.5, 110.3, 60.0, 41.7, 32.6, 31.5, 25.5, 22.5.

25

Preparation 22: *N'*-[1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthio-carbamoyl]-2-phenylethyl]-2(R)-phenylpropyl-succinamic acid (compound 222).

General procedure 3.

Starting materials: 2(R)-phenylpropyl-succinic acid 4-*tert*-butyl ester and L-thionophenylalanine *N*-[2-(2-methoxy-ethoxymethoxy)-ethyl]amide (prepared as described for compound 205).

¹³C NMR (CDCl₃) δ 202.0, 141.7, 136.6, 129.3, 128.5, 128.4, 128.3, 126.9,
5 125.9, 95.5, 71.8, 66.8, 65.5, 60.5, 58.9, 45.8, 42.5, 42.1, 35.6, 31.7, 29.7, 28.8.

Preparation 23: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-4-methylpentanoic acid [1(S)-(methylthiocarbamoyl)-2,2-dimethyl-propyl]-amide (compound 223).

10 General procedure 4.

Starting materials: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-4-methylpentanoic acid and L-thionot~~err~~butylglycine *N*-methylamide hydrochloric acid salt (prepared as described for compound 205).

¹³C NMR (CDCl₃) δ 202.0, 171.9, 170.5, 110.9, 74.8, 65.2, 47.7, 37.0, 35.7,
15 32.5, 26.9, 26.8, 25.8, 25.7, 23.2, 21.9.

Preparation 24: 3(S)-Allyl-2(R)-isobutyl-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2,2-dimethyl-propyl}-succinamic acid (compound 224).

General procedure 3.

20 Starting materials: 3(R,S)-allyl-2(R)-isobutyl-succinic acid-4-*tert*-butyl ester and L-thionot~~err~~butylglycine *N*-methylamide hydrochloric acid salt (prepared as described for compound 205).

¹³C NMR (CDCl₃) δ 200.8, 175.6, 174.9, 135.1, 117.7, 71.9, 70.3, 68.1, 65.2,
25 59.0, 47.6, 46.0, 45.5, 39.2, 36.0, 34.6, 27.0, 25.9, 23.7, 21.7.

Preparation 25: 3(S)-Allyl-2(R)-isobutyl-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)ethyl}-succinamic acid (compound 225).

General procedure 3.

Starting materials: 3(R,S)-allyl-2(R)-isobutyl-succinic acid-4-*tert*-butyl ester and L-thiono-4-methoxy-phenylalanine *N*-[2-(2-methoxy-ethoxy)-ethyl]amide (prepared as described for compound 205).

¹³C NMR (CDCl₃) δ 201.7, 175.5, 174.4, 158.8, 135.1, 130.3, 128.3, 117.7,
5 114.0, 71.8, 70.1, 68.1, 60.4, 58.9, 55.2, 47.2, 45.6, 41.4, 38.5, 34.4, 25.9, 23.7, 21.5.

Preparation 26: 2(R)-isobutyl-*N'*-[1(S)-(methylthiocarbamoyl)-2-methyl-propyl]-3(S)-propyl-succinamic acid (compound 226).

General procedure 3.

10 Starting materials: 2(R)-isobutyl-3(S)-propyl-succinic acid-4-*tert*-butyl ester and L-thionovaline *N*-methylamide hydrochloric acid salt (prepared as described for compound 205).

¹H NMR (CDCl₃) δ 9.07 (q,1H), 7.12 (d,1H), 4.53 (t,1H), 3.14
(d,3H), 2.60 (d,2H), 2.19 (m,1H), 1.65 (m,2H), 1.41 (m,4H), 1.05-0.80 (m,17H).

15

Preparation 27: 2(R)-isobutyl-*N'*-(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl})-3-methyl-butyl)-3(S)-propyl-succinamic acid (compound 227).

General procedure 3.

20 Starting materials: 2(R)-isobutyl-3(S)-propyl-succinic acid-4-*tert*-butyl ester and L-thionoleucine *N*-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl}amide (prepared as described for compound 205).

¹³C NMR (CDCl₃) δ 204.3, 177.7, 174.2, 71.9, 70.6, 70.4, 70.3, 68.0, 59.0,
57.1, 48.3, 47.4, 45.6, 45.2, 40.0, 32.9, 25.9, 24.9, 23.7, 22.9, 22.2, 21.6, 20.7, 13.9.

25 Preparation 28: 2(R)-Dodecyl-*N'*-[1(S)-(methylthiocarbamoyl)-3-methyl-butyl]-succinamic acid (compound 228).

General procedure 3.

30 Starting materials: 2(R)-dodecyl-succinic acid-4-*tert*-butyl ester and L-thionoleucine *N*-methylamide hydrochloric acid salt (prepared as described for compound 205).

^{13}C NMR (CDCl_3) δ 205.0, 177.2, 175.4, 57.5, 44.4, 42.9, 36.9, 32.7, 32.5, 31.9, 29.7, 29.6, 29.5, 29.4, 27.2, 24.8, 22.8, 22.7, 22.1, 14.1.

5 Preparation 29: 2(R)-Dodecyl- N' -[1(S)-(phenylethylthiocarbamoyl)-2-methyl-butyl]-succinamic acid (compound 229).

General procedure 3.

Starting materials: 2(R)-dodecyl-succinic acid-4-*tert*-butyl ester and L-thionoisoleucine *N*-phenylethylamide hydrochloric acid salt (prepared as described for compound 205).

10 ^{13}C NMR (CDCl_3) δ 203.5, 176.8, 175.3, 138.2, 128.6, 126.6, 63.6, 46.7, 43.0, 39.2, 37.1, 33.6, 32.7, 31.9, 29.7, 29.6, 29.4, 27.3, 24.8, 22.7, 15.3, 14.1, 10.9.

Preparation 30: 2(R)-Hexadecyl- N' -[1(S)-(phenylthiocarbamoyl)-ethyl]-succinamic acid (compound 230).

15 General procedure 3.

Starting materials: 2(R)-hexadecyl-succinic acid-4-*tert*-butyl ester and L-thionoalanine *N*-phenylamide hydrochloric acid salt (prepared as described for compound 205).

20 ^1H NMR (CDCl_3) δ 10.67(s,1H), 7.76 (d,2H), 7.36 (t,2H), 7.22 (t,1H), 6.96(d,1H), 5.16 (m,1H), 2.68 (m,2H), 2.45 (m,1H), 1.62(m,1H), 1.49 (d,3H), 1.25 (m,30H), 0.87 (t,3H).

Preparation 31: 2(R)-Hexadecyl- N' -[1(S)-(methylthiocarbamoyl)-2,2-dimethyl-propyl]-succinamic acid (compound 231).

25 General procedure 3.

Starting materials: 2(R)-hexadecyl-succinic acid-4-*tert*-butyl ester and L-thionoisoleucine *N*-methylamide hydrochloric acid salt (prepared as described for compound 205).

^1H NMR ($\text{DMSO-}d_6$) δ 12.7(s,1H), 10.08 (q,1H), 7.37 (d,1H), 4.62 (d,1H), 2.94(d,3H), 2.74 (m,1H), 2.4 (dd,1H), 2.25 (dd,1H), 1.40(m,1H), 1.35-1.05 (m,29H), 0.92 (s,9H), 0.85 (t,3H).

5 Preparation 32: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-(3-phenyl)propanoic acid {1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)-ethyl}-amide (compound 232).

General procedure 4.

Starting materials: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-5-phenylpentanoic acid and L-thiono-4-methoxy-phenylalanine *N*-[2-(2-methoxy-ethoxy)-ethyl]amide (prepared as described for compound 205).

^{13}C NMR (CDCl_3) δ 201.9, 172.0, 169.8, 158.7, 141.8, 130.3, 128.6, 128.4, 128.4, 125.9, 114.0, 111.0, 74.4, 71.8, 70.2, 68.0, 61.2, 59.0, 55.2, 49.0, 45.4, 41.2, 35.6, 28.8, 27.4, 26.9, 25.9.

15

Preparation 33: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-(3-phenyl)propanoic acid {1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-amide (compound 233).

General procedure 4.

20 Starting materials: 2(R)-(2,2-dimethyl-5-oxo-[1,3]dioxalan-4(S)-yl)-5-phenylpentanoic acid and L-thiono-valine *N*-[2-(2-methoxy-ethoxymethoxy)-ethyl]amide (prepared as described for compound 205).

^{13}C NMR (CDCl_3) δ 203.6, 172.1, 170.2, 141.8, 128.4, 128.3, 125.8, 110.8, 95.9, 74.4, 71.9, 67.0, 66.2, 64.3, 59.1, 49.5, 46.0, 35.6, 33.9, 28.7, 27.5, 27.0, 26.0, 19.5, 18.3.

25

Preparation 34: 2(R)-(4-chlorophenyl)propyl-*N'*-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)ethyl}-succinamic acid (compound 234).

30

General procedure 3.

Starting materials: 2(R)-(4-chlorophenyl)propyl-succinic acid-4-*tert*-butyl ester and L-thiono-4-methoxy-phenylalanine *N*-[2-(2-methoxy-ethoxy)-ethyl]amide (prepared as described for compound 205).

¹³C NMR (CDCl₃) δ 202.0, 174.7, 174.1, 158.7, 140.1, 131.6, 130.3, 129.8,
5 128.6, 128.5, 114.0, 71.8, 70.1, 68.1, 61.0, 58.9, 55.2, 45.6, 42.6, 41.1, 36.4, 34.9,
31.6, 28.6.

Preparation 35: 2(R)-(4-chlorophenyl)propyl-*N*¹-(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-3-methyl-butyl)-succinamic acid (compound
10 235).

General procedure 3.

Starting materials: 2(R)-(4-chlorophenyl)propyl-succinic acid-4-*tert*-butyl ester and L-thionoleucine *N*-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl}amide (prepared as described for compound 205).

15 ¹³C NMR (CDCl₃) δ 204.5, 175.1, 174.5, 140.2, 131.6, 129.8, 128.4, 71.9,
70.5, 70.3, 70.2, 68.1, 58.9, 57.5, 45.6, 44.9, 42.5, 36.5, 34.9, 31.8, 28.7, .4.8, 22.9,
22.1.

Preparation 36: 2(R)-(4-chlorophenyl)propyl-*N*¹-(1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl)-succinamic acid (compound
20 236).

General procedure 3.

Starting materials: 2(R)-(4-chlorophenyl)propyl-succinic acid-4-*tert*-butyl ester and L-thionovaline *N*-[2-(2-methoxy-ethoxymethoxy)-ethyl]amide (prepared as
25 described for compound 205).

¹³C NMR (CDCl₃) δ 203.7, 176.1, 174.7, 140.3, 131.5, 129.8, 128.4, 95.8,
71.9, 67.1, 65.7, 64.4, 59.0, 45.8, 42.9, 37.3, 34.9, 33.7, 32.0, 28.6, 19.4, 18.6.

Preparation 37: 2(R)-(4-chlorophenyl)propyl-*N*¹-[1(S)-(methylthio-carbamoyl)-2-(1*H*-indol-3-yl)ethyl]-succinamic acid (compound 237).
30

General procedure 3.

Starting materials: 2(R)-(4-chlorophenyl)propyl-succinic acid-4-*tert*-butyl ester and L-thionotryptophane *N*-methylamide hydrochloric acid salt (prepared as described for compound 205).

5 ^{13}C NMR (DMSO- d_6) δ 203.6, 173.9, 173.8, 141.0, 135.9, 130.0, 127.9, 127.2, 123.5, 120.7, 118.3, 118.0, 111.2, 110.3, 59.8, 42.1, 37.8, 34.2, 32.1, 31.6, 30.4, 28.1.

Preparation 38: N^1 -(1(S)-[2-(2-methoxy-ethoxymethoxy)-ethyl]-thiocarbamoyl]-2-methyl-propyl}-2(R)-(4-methylphenoxy)ethyl-succinamic acid (compound 238).

General procedure 3.

Starting materials: 2(R)-(4-methylphenoxy)ethyl-succinic acid-4-*tert*-butyl ester and L-thionovaline *N*-[2-(2-methoxy-ethoxymethoxy)-ethyl]amide (prepared as described for compound 205).

15 ^{13}C NMR (CDCl₃) δ 203.5, 175.4, 174.2, 156.4, 130.2, 129.9, 114.6, 95.8, 71.9, 67.0, 65.9, 65.3, 64.6, 59.0, 45.9, 39.5, 36.4, 33.8, 31.9, 20.5, 19.4, 18.5.

Preparation 39: N^1 -(1(S)-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl]thiocarbamoyl]-(4-methoxyphenyl)ethyl)-2(R)-(4-methylphenoxy)ethyl-succinamic acid (compound 239).

General procedure 3.

Starting materials: 2(R)-(4-methylphenoxy)ethyl-succinic acid-4-*tert*-butyl ester and L-thiono-4-methoxy-phenylalanine *N*-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl}amide (prepared as described for compound 205).

25 ^1H NMR (CDCl₃) δ 8.39(t,1H), 7.11 (d,2H), 7.04 (d,2H), 6.92 (d,1H), 6.79(d,2H), 6.73 (d,2H), 4.80 (q,1H), 3.88 (t,2H), 3.75(s,3H), 3.8-3.4 (m,12H), 3.36 (s,3H), 3.13 (d,2H), 2.92(m,1H), 2.71 (dd,1H), 2.59 (dd,1H), 2.27 (s,3H), 2.00 (m,2H).

30

Preparation 40: N^1 -[1(S)-(methylthiocarbamoyl)-2-(1*H*-indol-3-yl)ethyl]-2(R)-(4-methylphenoxy)ethyl-succinamic acid (compound 240).

General procedure 3.

Starting materials: 2(R)-(4-methylphenoxy)ethyl-succinic acid-4-*tert*-butyl ester and L-thionotryptophane *N*-methylamide hydrochloric acid salt (prepared as described for compound 205).

^{13}C NMR (CDCl_3) δ 203.2, 177.6, 175.7, 156.2, 136.1, 130.4, 130.0, 127.4, 123.6, 122.1, 119.5, 118.8, 114.5, 111.5, 110.2, 65.6, 60.3, 40.3, 38.6, 32.6, 31.9, 31.3, 20.4.

10

Example 1: N^4 -Hydroxy-2(R)-phenylethyl- N^1 -[1(S)-(3-phenylpropyl-thiocarbamoyl)-2-phenylethyl]-succinamide (compound 101).

General procedure 7.

Starting material: compound 209.

^{13}C NMR (DMSO-d_6) δ 202.7, 173.2, 167.4, 141.9, 141.4, 137.6, 129.1, 128.2, 128.1, 128.1, 127.9, 126.2, 125.6, 125.5, 60.0, 44.4, 41.4, 34.6, 33.5, 32.4, 32.3, 28.6.

15

Example 2: N^4 -Hydroxy-2(R)-isobutyl- N^1 -[1(S)-(3-phenylpropyl-thiocarbamoyl)-2-phenylethyl]-succinamide (compound 102).

20

General procedure 7.

Starting material: compound 210.

^{13}C NMR (DMSO-d_6) δ 202.5, 173.5, 167.4, 141.4, 137.7, 129.0, 128.1, 127.9, 126.1, 125.7, 59.9, 44.4, 40.5, 40.2, 35.6, 32.2, 28.6, 25.0, 23.2, 21.8.

25

Example 3: N^4 -Hydroxy-2(R)-isobutyl- N^1 -[1(S)-(methylthiocarbamoyl)-2-phenylethyl]-succinamide (compound 103).

General procedure 7.

Starting material: compound 211.

30

^{13}C NMR (CDCl_3) δ 202.7, 174.9, 168.9, 136.5, 129.2, 128.6, 127.0, 60.3, 42.0, 41.4, 36.2, 32.7, 25.7, 22.9, 22.1.

5 Example 4: N^4 -Hydroxy- N^1 -[1(S)-(methylthiocarbamoyl)-2-phenylethyl]-2(R)-phenylpropyl-succinamide (compound 104).

General procedure 7.

Starting material: compound 212.

^{13}C NMR ($\text{DMSO}-d_6$) δ 203.1, 173.4, 167.6, 142.0, 137.9, 128.9, 128.1, 128.0, 127.9, 126.2, 125.5, 60.1, 41.8, 40.1, 35.0, 34.7, 32.0, 31.3, 28.3.

10

Example 5: N^4 -Hydroxy-2(R)-phenylpropyl- N^1 -[1(S)-(3-phenylpropyl-thiocarbamoyl)-2-phenylethyl]-succinamide (compound 105).

General procedure 7.

Starting material: compound 213.

15 ^{13}C NMR (CDCl_3) δ 201.5, 174.6, 169.0, 141.7, 141.0, 136.3, 129.3, 128.6, 128.4, 128.3, 128.3, 127.1, 126.0, 125.9, 60.7, 45.3, 43.1, 41.5, 35.5, 35.3, 32.9, 32.1, 28.8, 28.6.

20 Example 6: N^4 -Hydroxy-2(R)-phenylpropyl- N^1 -[1(S)-(3-phenylpropyl-thiocarbamoyl)-2-cyclohexylethyl]-succinamide (compound 106).

General procedure 7.

Starting material: compound 214.

25 ^{13}C NMR (CDCl_3) δ 203.8, 174.9, 169.0, 141.6, 141.2, 128.5, 128.4, 126.1, 125.9, 57.2, 45.5, 43.0, 42.6, 35.5, 34.0, 33.3, 33.2, 33.0, 32.4, 29.2, 28.7, 26.4, 26.1, 25.9.

Example 7: N^4 -Hydroxy- N^1 -[1(S)-(methylthiocarbamoyl)-2-cyclohexylethyl]-2(R)-phenylpropyl-succinamide (compound 107).

General procedure 7.

30 Starting material: compound 215.

^{13}C NMR ($\text{DMSO}-d_6$) δ 204.8, 173.5, 167.6, 142.0, 128.1, 128.0, 125.5, 56.5, 42.0, 41.8, 35.1, 34.8, 33.5, 33.1, 32.0, 31.6, 31.6, 28.4, 26.0, 25.7, 25.4.

5 Example 8: N^4 -Hydroxy-2(R)-isobutyl- N^1 -thiono- N^1 -[1(S)-(methyl-carbamoyl)-2-phenylethyl]-succinamide (compound 108).

General procedure 7.

Starting material: compound 216.

MS $[\text{M}-\text{H}]^-$ 364, $[\text{M}-\text{OH}]^-$ 348, $[\text{M}-\text{NH}_2\text{OH}]^-$ 331.

10 Example 9: 3(S), N^4 -Dihydroxy-2(R)-isobutyl- N^1 -[1(S)-(methylthio-carbamoyl)-2-cyclohexylethyl]-succinamide (compound 109).

General procedure 8.

Starting material: compound 217.

15 ^{13}C NMR (CDCl_3) δ 204.2, 174.5, 169.8, 71.2, 57.3, 47.2, 42.9, 38.9, 34.4, 33.7, 33.0, 32.3, 26.3, 26.2, 26.0, 25.8, 23.0, 22.1.

Example 10: 3(S), N^4 -Dihydroxy-2(R)-isobutyl- N^1 -[1(S)-(methylthio-carbamoyl)-2-phenylethyl]-succinamide (compound 110).

General procedure 8.

20 Starting material: compound 218.

MS $[\text{MH}]^+$ 382, $[\text{MNa}]^+$ 404, $[\text{MH}-\text{NH}_2\text{OH}]^+$ 349.

Example 11: N^4 -Hydroxy-2(R)-isobutyl- N^1 -[1(S)-(3-phenylpropyl-thiocarbamoyl)-2-cyclohexylethyl]-succinamide (compound 111).

25 General procedure 7.

Starting material: compound 219.

^{13}C NMR (CD_3OD) δ 205.9, 176.7, 170.6, 142.9, 129.5, 129.4, 127.0, 58.3, 46.1, 43.9, 42.6, 42.4, 37.1, 35.5, 34.7, 34.3, 33.9, 30.6, 27.7, 27.4, 27.2, 26.9, 23.8, 22.4.

30

Example 12: N^4 -Hydroxy-2(R)-isobutyl- N^1 -[1(S)-(3-methylthiocarbamoyl)-2-cyclohexylethyl]-succinamide (compound 112).

General procedure 7.

Starting material: compound 220.

5 ^{13}C NMR (CD_3OD) δ 206.6, 176.8, 58.2, 43.9, 42.7, 37.1, 35.5, 34.9, 33.6, 32.7, 27.7, 27.4, 27.2, 26.9, 23.8, 22.4, 15.5.

Example 13: N^4 -Hydroxy-2(R)-isobutyl- N^1 -[1(S)-(3-methylthiocarbamoyl)-2-(1H-indol-3-yl)ethyl]-succinamide (compound 113).

10 General procedure 7.

Starting material: compound 221.

^{13}C NMR ($\text{DMSO}-d_6$) δ 204.4, 174.4, 168.4, 136.8, 128.1, 124.4, 121.6, 119.2, 118.9, 112.0, 111.0, 60.5, 41.4, 36.3, 33.0, 31.4, 25.8, 23.9, 22.8.

Example 14: N^4 -Hydroxy- N^1 -[1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-phenylethyl]-2(R)-phenylpropyl-succinamide (compound 114).

15

General procedure 7.

Starting material: compound 222.

20 ^{13}C NMR (CDCl_3) δ 202.2, 174.1, 141.7, 136.6, 129.3, 128.5, 128.4, 128.3, 126.9, 125.9, 95.6, 71.8, 66.9, 65.4, 60.7, 58.9, 45.8, 43.3, 41.8, 35.5, 32.0, 29.7, 28.7.

Example 15: 3(S), N^4 -Dihydroxy-2(R)-isobutyl- N^1 -[1(S)-(methylthiocarbamoyl)-2,2-dimethyl-propyl]-succinamide (compound 115).

25 General procedure 8.

Starting material: compound 223.

^{13}C NMR ($\text{DMSO}-d_6$) δ 201.7, 171.6, 168.8, 71.6, 64.3, 48.3, 35.2, 31.8, 26.9, 26.8, 25.2, 23.6, 21.7.

Example 16: 3(S)-Allyl-*N*⁴-hydroxy-2(R)-isobutyl-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2,2-dimethyl-propyl}-succinamide (compound 116).

General procedure 9.

Starting material: compound 224.

5 ¹³C NMR (DMSO-*d*₆) δ 201.6, 173.0, 169.2, 135.9, 116.2, 71.2, 69.4, 67.1, 64.6, 58.1, 46.3, 45.9, 44.7, 34.9, 34.5, 26.9, 25.1, 24.2, 21.7.

Example 17: 3(S)-Allyl-*N*⁴-hydroxy-2(R)-isobutyl-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)ethyl}-succinamide (compound 117).

10

General procedure 9.

Starting material: compound 225.

15 ¹³C NMR (DMSO-*d*₆) δ 204.4, 172.8, 169.2, 157.7, 135.8, 130.3, 129.5, 115.5, 113.2, 71.1, 69.4, 67.1, 60.0, 58.0, 54.6, 45.9, 45.6, 44.9, 34.2, 24.9, 24.2, 21.5.

Example 18: *N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-[1(S)-(methylthiocarbamoyl)-2-methyl-propyl]-3(S)-propyl-succinamide (compound 118).

General procedure 9.

20 Starting material: compound 226.

15 ¹³C NMR (DMSO-*d*₆) δ 204.1, 173.2, 170.0, 64.4, 46.1, 45.7, 32.7, 31.7, 31.5, 25.0, 24.1, 21.6, 19.9, 19.2, 18.9, 13.8.

Example 19: *N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-3-methyl-butyl)-3(S)-propyl-succinamide (compound 119).

25

General procedure 9.

Starting material: compound 227.

30 ¹³C NMR (DMSO-*d*₆) δ 206.0, 173.8, 170.4, 71.7, 70.1, 70.0, 67.5, 58.5, 57.3, 46.6, 46.3, 45.3, 44.0, 33.3, 25.5, 24.7, 23.6, 22.0, 20.5, 14.4.

Example 20: 2(R)-Dodecyl-*N*⁴-hydroxy-*N*¹-[1(S)-(methylthiocarbamoyl)-3-methyl-butyl]-succinamide (compound 120).

General procedure 7.

5 Starting material: compound 228.

¹³C NMR (CDCl₃) δ 204.7, 175.0, 169.3, 57.6, 43.8, 43.5, 33.1, 32.7, 31.9, 29.7, 29.4, 27.2, 24.9, 22.9, 22.7, 22.2, 14.1.

Example 21: 2(R)-Dodecyl-*N*⁴-hydroxy-*N*¹-[1(S)-(phenylethylthiocarbamoyl)-2-methyl-butyl]-succinamide (compound 121).

General procedure 7.

Starting material: compound 229.

¹³C NMR (DMSO-*d*₆) δ 203.5, 173.5, 167.5, 138.8, 128.4, 128.2, 126.1, 62.7, 46.0, 41.4, 37.8, 34.9, 32.8, 31.8, 31.2, 29.1, 29.0, 28.9, 28.9, 28.9, 28.6, 26.4, 24.2, 22.0, 15.1, 13.8, 10.7.

Example 22: 2(R)-Hexadecyl-*N*⁴-hydroxy-*N*¹-[1(S)-(phenylthiocarbamoyl)-ethyl]-succinamide (compound 122).

General procedure 7.

20 Starting material: compound 230.

¹³C NMR (DMSO-*d*₆) δ 204.9, 173.7, 167.7, 139.4, 128.4, 125.9, 122.8, 55.6, 41.5, 34.8, 32.0, 31.3, 29.1, 28.7, 26.5, 22.1, 21.0, 14.0.

Example 23: 2(R)-Hexadecyl-*N*⁴-hydroxy-*N*¹-[1(S)-(methylthiocarbamoyl)-2,2-dimethyl-propyl]-succinamide (compound 123).

General procedure 7.

Starting material: compound 231.

¹³C NMR (DMSO-*d*₆) δ 201.7, 173.3, 167.4, 64.3, 41.6, 35.0, 34.7, 31.7, 31.6, 31.2, 29.0, 28.8, 28.6, 26.7, 26.4, 22.0, 13.8.

30

Example 24: 3(S), *N'*-Dihydroxy-*N'*-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)-ethyl}-2(R)-phenylpropyl-succinamide (compound 124).

General procedure 8.

5 Starting material: compound 232.

¹³C NMR (CDCl₃) δ 201.9, 173.4, 169.6, 158.6, 141.7, 130.3, 128.4, 128.4, 125.9, 113.9, 72.2, 71.7, 69.9, 68.2, 61.3, 58.9, 55.2, 48.4, 45.5, 40.3, 35.5, 29.4, 28.7.

10 Example 25: 3(S), *N'*-Dihydroxy-*N'*-{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-2(R)-phenylpropyl-succinamide (compound 125).

General procedure 8.

Starting material: compound 233.

15 ¹³C NMR (DMSO-*d*₆) δ 203.1, 174.1, 169.6, 141.7, 128.4, 128.4, 125.9, 95.7, 72.3, 71.9, 67.0, 65.6, 64.8, 59.0, 47.8, 45.8, 35.5, 33.3, 29.5, 28.8, 19.4, 18.4.

20 Example 26: *N'*-Hydroxy-2(R)-(4-chlorophenyl)propyl-*N'*-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)ethyl}-succinamide (compound 126).

General procedure 7.

Starting material: compound 234.

25 ¹³C NMR (DMSO-*d*₆) δ 203.6, 173.3, 167.5, 157.7, 141.0, 130.1, 130.0, 129.5, 127.9, 113.3, 71.1, 69.3, 66.9, 60.1, 58.0, 54.8, 44.7, 41.5, 34.7, 34.2, 31.0, 28.1.

Example 27: *N'*-Hydroxy-2(R)-(4-chlorophenyl)propyl-*N'*-(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-3-methyl-butyl)-succinamide (compound 127).

30 General procedure 7.

Starting material: compound 235.

^{13}C NMR (DMSO- d_6) δ 205.0, 173.4, 167.5, 141.0, 130.0, 127.9, 71.2, 69.6, 69.5, 66.9, 58.0, 57.1, 44.7, 43.6, 41.4, 34.8, 34.2, 31.3, 28.2, 24.1, 22.8, 21.6.

5 Example 28: N^4 -Hydroxy-2(R)-(4-chlorophenyl)propyl- N^1 -{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-succinamide (compound 128).

General procedure 7.

Starting material: compound 236.

10 ^{13}C NMR (DMSO- d_6) δ 203.9, 173.4, 167.5, 141.0, 130.0, 127.9, 94.6, 71.1, 66.2, 64.0, 57.9, 44.7, 41.1, 34.9, 34.2, 32.2, 31.3, 28.1, 19.1, 18.5.

Example 29: N^4 -Hydroxy-2(R)-(4-chlorophenyl)propyl- N^1 -[1(S)-(methylthiocarbamoyl)-2-(1H-indol-3-yl)ethyl]-succinamide (compound 129).

15 General procedure 7.

Starting material: compound 237.

^{13}C NMR (DMSO- d_6) δ 203.7, 173.4, 167.6, 141.0, 135.9, 130.0, 127.9, 127.2, 123.6, 120.7, 118.3, 118.1, 111.2, 110.1, 59.7, 41.8, 34.7, 34.2, 32.1, 31.2, 30.5, 28.1.

20

Example 30: N^4 -Hydroxy- N^1 -{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-2(R)-(4-methylphenoxy)ethyl-succinamide (compound 130).

General procedure 7.

25 Starting material: compound 238.

^{13}C NMR (CDCl_3) δ 203.5, 174.0, 168.4, 156.4, 130.2, 129.9, 114.6, 95.8, 71.9, 67.1, 65.8, 65.5, 65.0, 59.0, 45.8, 40.5, 35.4, 33.5, 32.2, 20.5, 19.4, 18.6.

Example 31: *N*⁴-Hydroxy-*N*¹-(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-(4-methoxyphenyl)ethyl)-2(R)-(4-methylphenoxy)ethyl-succinamide (compound 131).

General procedure 7.

5 Starting material: compound 239.

¹³C NMR (CDCl₃) δ 202.5, 173.8, 168.7, 158.5, 156.4, 130.3, 130.1, 129.9, 128.8, 114.5, 113.9, 71.9, 70.4, 70.3, 70.1, 68.2, 65.4, 61.7, 58.9, 55.2, 45.4, 40.4, 40.3, 35.3, 31.8, 20.5.

10 Example 32: *N*⁴-Hydroxy-*N*¹-[1(S)-(methylthiocarbamoyl)-2-(1*H*-indol-3-yl)ethyl]-2(R)-(4-methylphenoxy)ethyl-succinamide (compound 132).

General procedure 7.

Starting material: compound 240.

15 ¹³C NMR (DMSO-*d*₆) 203.7, 172.9, 167.3, 156.2, 135.9, 129.6, 128.9, 127.2, 123.7, 120.7, 118.4, 118.1, 114.1, 111.2, 110.0, 65.3, 59.8, 34.8, 32.1, 31.0, 30.5, 20.0.

Example 33: Capsules containing compound 103.

Compound 103 was dissolved in fractionated coconut oil to a final
20 concentration of 10 mg/ml. Ten parts by weight of gelatine, 5 parts by weight of glycerin, 0.08 parts by weight of potassium sorbate, and 14 parts by weight of distilled water were mixed together with heating and formed into soft gelatine capsules. These were then filled each with 500 µl of the oily solution of compound 103.

25

Example 34: Tablet containing compound 103.

Compound 103

(active substance) 50 mg

Lactose 125 mg

30 Starch 12 mg

Methyl cellulose	2 mg
Sodium carboxymethyl cellulose	10 mg
Magnesium stearate	1 mg

5 The active substance, lactose and starch are mixed to a homogeneous state in a suitable mixer and moistened with a 5 per cent aqueous solution of methyl cellulose 15 cps. The mixing is continued until granules are formed. If necessary, the wet granulation is passed through a suitable screen and dried to a water content of less than 1% in a suitable drier, e.g. fluid bed or drying oven. The dried granules are
10 passed through a 1 mm screen and mixed to a homogeneous state with sodium carboxymethyl cellulose. Magnesium stearate is added, and the mixing is continued for a short period of time.

Tablets with a weight of 200 mg are produced from the granulation by means of a suitable tableting machine.

15


Example 35: Formulation for injection containing compound 103.

Compound 103	
(active substance)	1%
Sodium chloride	q.s.
20 Ethanol	10%
Water for injection to make	100%

The active substance is dissolved in ethanol (10%) then water for injection made isotonic with sodium chloride is added to make 100%. The mixture is filled
25 into ampoules and sterilized.

WHAT WE CLAIM IS:

1. A compound of the general formula (I)



5

wherein X is a -CO₂H or -CONHOH group; Y and Z are independently sulphur or oxygen, at least one being sulphur; R₁ is hydrogen, hydroxy, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₃-C₈)cycloalkyl; R₂ is a (C₁-C₂₄)alkyl, phenyl(C₁-C₆)alkyl, or phenyl(C₀-C₆ alkyl)O(C₁-C₆)alkyl, any of which may be optionally substituted with (C₁-C₆)alkyl, (C₁-C₆)alkoxy, halo, or cyano (CN); R₃ is the characterising side chain of a natural α-amino acid in which any functional groups may be protected, (C₁-C₆)alkyl which may be optionally substituted, or cycloalkyl(C₁-C₆)alkyl; R₄ is hydrogen, (C₁-C₆)alkyl, phenyl(C₁-C₆)alkyl, optionally substituted phenyl or heteroaryl, or a group of formula -(Q-O)_n-Q where Q is (C₁-C₆)alkyl and where n is an integer >1, and no continuous linear sequence of atoms in the group R₄ is >12; any of the above alkyl or alkenyl groups being straight or branched; or a salt, hydrate or solvate thereof.

2. A diastereoisomer of a compound according to claim 1, in pure form; or a mixture of stereoisomers of a compound according to claim 1.
3. A compound according to any one of the preceding claims wherein R₁ is hydrogen, hydroxyl, allyl or propyl.

25

4. A compound according to any one of the preceding claims wherein R₂ is isobutyl, phenylpropyl, (4-chlorophenyl)propyl, (4-methylphenoxy)ethyl or (C₆-C₁₆)alkyl.
5. A compound according to any one of the preceding claims wherein R₃ is benzyl, t-butyl, cyclohexylmethyl, 4-methoxybenzyl, indolmethyl, isobutyl and isopropyl.
6. A compound according to any one of the preceding claims wherein R₄ is methyl, phenylpropyl, 2-(2-methoxyethoxy)ethyl, 2-(2-methoxyethoxymethoxy)ethyl or 2-(ethoxyethoxymethoxy)ethyl.
7. A compound according to claim 1 wherein R₁ is hydrogen, hydroxyl, allyl, or propyl; R₂ is isobutyl, phenylpropyl, (4-chlorophenyl)propyl, (4-methylphenoxy)ethyl, or (C₆-C₁₆)alkyl; R₃ is benzyl, t-butyl, cyclohexylmethyl, 4-methoxybenzyl, indolmethyl, isobutyl, or isopropyl; R₄ is methyl, phenylpropyl, 2-(2-methoxyethoxy)ethyl, 2-(2-methoxyethoxymethoxy)ethyl, or 2-(ethoxyethoxymethoxy)ethyl.
8. A compound according to the preceding claims which is selected from the group consisting of:
- N*⁴-Hydroxy-2(R)-phenylethyl-*N*¹-[1(S)-(3-phenylpropylthiocarbamoyl)-2-phenylethyl]-succinamide,
 - N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-[1(S)-(3-phenylpropylthiocarbamoyl)-2-phenylethyl]-succinamide,
 - N*⁴-Hydroxy-2(R)-isobutyl-*N*¹-[1(S)-(methylthiocarbamoyl)-2-phenylethyl]-succinamide,


- d) N^4 -Hydroxy- N' -[1(S)-(methylthiocarbamoyl)-2-phenylethyl]-2(R)-phenylpropyl]-succinamide,
- 5 e) N^4 -Hydroxy-2(R)-phenylpropyl- N' -[1(S)-(3-phenylpropylthiocarbamoyl)-2-phenylethyl]-succinamide,
- f) N^4 -Hydroxy-2(R)-phenylpropyl- N' -[1(S)-(3-phenylpropylthiocarbamoyl)-2-cyclohexylethyl]-succinamide,
- 10 g) N^4 -Hydroxy- N' -[1(S)-(methylthiocarbamoyl)-2-cyclohexylethyl]-2(R)-phenylpropyl]-succinamide,
- h) N^4 -Hydroxy-2(R)-isobutyl- N' -thiono- N' -[1(S)-(methylcarbamoyl)-2-phenylethyl]-succinamide,
- 15 i) 3(S), N^4 -Dihydroxy-2(R)-isobutyl- N' -[1(S)-(methylthiocarbamoyl)-2-cyclohexylethyl]-succinamide,
- j) 3(S), N^4 -Dihydroxy-2(R)-isobutyl- N' -[1(S)-(methylthiocarbamoyl)-2-phenylethyl]-succinamide,
- 20 k) N^4 -Hydroxy-2(R)-isobutyl- N' -[1(S)-(3-phenylpropylthiocarbamoyl)-2-cyclohexylethyl]-succinamide,
- l) N^4 -Hydroxy-2(R)-isobutyl- N' -[1(S)-(3-methylthiocarbamoyl)-2-cyclohexylethyl]-succinamide,
- 25 m) N^4 -Hydroxy-2(R)-isobutyl- N' -[1(S)-(3-methylthiocarbamoyl)-2-(1H-indol-3-yl)ethyl]-succinamide,
- 30

- n) N^4 -Hydroxy- N^1 -{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-phenylethyl}-2(R)-phenylpropyl-succinamide,
- o) 3(S), N^4 -Dihydroxy-2(R)-isobutyl- N^1 -[1(S)-(methylthiocarbamoyl)-2,2-dimethyl-propyl]-succinamide,
- p) 3(S)-Allyl- N^4 -hydroxy-2(R)-isobutyl- N^1 -{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2,2-dimethyl-propyl}-succinamide,
- q) 3(S)-Allyl- N^4 -hydroxy-2(R)-isobutyl- N^1 -{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)ethyl}-succinamide,
- r) N^4 -Hydroxy-2(R)-isobutyl- N^1 -[1(S)-(methylthiocarbamoyl)-2-methyl-propyl]-3(S)-propyl-succinamide,
- s) N^4 -Hydroxy-2(R)-isobutyl- N^1 -(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-3-methyl-butyl)-3(S)-propyl-succinamide,
- t) 2(R)-Dodecyl- N^4 -hydroxy- N^1 -[1(S)-(methylthiocarbamoyl)-3-methyl-butyl]-succinamide,
- u) 2(R)-Dodecyl- N^4 -hydroxy- N^1 -[1(S)-(phenylethylthiocarbamoyl)-2-methyl-butyl]-succinamide,
- v) 2(R)-Hexadecyl- N^4 -hydroxy- N^1 -[1(S)-(phenylthiocarbamoyl)-ethyl]-succinamide,
- w) 2(R)-Hexadecyl- N^4 -hydroxy- N^1 -[1(S)-(methylthiocarbamoyl)-2,2-dimethyl-propyl]-succinamide,

- x) 3(S), *N*⁴-Dihydroxy-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)-ethyl}-2(R)-phenylpropyl-succinamide,
- 5 y) 3(S), *N*⁴-Dihydroxy-*N*¹-{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-2(R)-phenylpropyl-succinamide,
- z) *N*⁴-Hydroxy-2(R)-(4-chlorophenyl)propyl-*N*¹-{1(S)-[2-(2-methoxy-ethoxy)-ethylthiocarbamoyl]-2-(4-methoxyphenyl)ethyl}-succinamide,
- 10 aa) *N*⁴-Hydroxy-2(R)-(4-chlorophenyl)propyl-*N*¹-(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-3-methyl-butyl)-succinamide,
- bb) *N*⁴-Hydroxy-2(R)-(4-chlorophenyl)propyl-*N*¹-{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-succinamide,
- 15 cc) *N*⁴-Hydroxy-2(R)-(4-chlorophenyl)propyl-*N*¹-[1(S)-(methylthiocarbamoyl)-2-(1*H*-indol-3-yl)ethyl]-succinamide,
- dd) *N*⁴-Hydroxy-*N*¹-{1(S)-[2-(2-methoxy-ethoxymethoxy)-ethylthiocarbamoyl]-2-methyl-propyl}-2(R)-(4-methylphenoxy)ethyl-succinamide,
- 20 ee) *N*⁴-Hydroxy-*N*¹-(1(S)-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylthiocarbamoyl}-(4-methoxyphenyl)ethyl)-2(R)-(4-methylphenoxy)ethyl-succinamide;
- 25 ff) *N*⁴-Hydroxy-*N*¹-[1(S)-(methylthiocarbamoyl)-2-(1*H*-indol-3-yl)ethyl]-2(R)-(4-methylphenoxy)ethyl-succinamide;

a diastereoisomer of any one of said compounds in pure form; a mixture of stereoisomers of any one of said compounds; and a pharmaceutically acceptable salt, hydrate, or solvate of any one of said compounds.

- 5 9. A method for producing a compound of formula I of claim 1 by which an acid of general formula (II)



- 10 is reacted with hydroxylamine, O-protected hydroxylamine, or N,O-diprotected hydroxylamine, the acid of formula (II) possibly protected from said reaction, whereafter removing any protecting groups from the resulting hydroxamic acid moiety and from any protected substituents in R₁, R₂, R₃, and R₄.
- 15 10. A pharmaceutical composition containing an effective amount of one or more of the compounds of claims 1-8 as an active ingredient, together with pharmaceutically acceptable carriers and/or auxiliary agents.
11. A pharmaceutical composition according to claim 10 in dosage
20 unit form for systemic treatment containing from 0.07 mg to 1 g of one or more of the compounds of claims 1-8 as an active ingredient.
12. A pharmaceutical composition according to claim 10 in dosage
unit form containing from 0.5 mg to about 500 mg of one or more of the
25 compounds of claims 1-8 as an active ingredient.

13. A method for the treatment or prophylaxis of conditions involving tissue breakdown and inflammation, for example rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, and tumour metastasis, invasion and growth, and
5 for the treatment of neuroinflammatory disorders, including those involving myelin degradation, for example multiple sclerosis, as well as for the management of angiogenesis dependent diseases, which include arthritic conditions and solid tumour growth as well as psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angiofibromas and hemangiomas, consisting in
10 administering to a patient in need thereof a pharmaceutical composition according to claim 10, 11 or 12.
14. The use of a compound according to any one of claims 1-8 in the manufacture of a medicament for the treatment or prophylaxis of conditions
15 involving tissue breakdown and inflammation, for example rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, and tumour metastasis, invasion and growth, and for the treatment of neuroinflammatory disorders, including those involving myelin degradation, for example multiple sclerosis, as well as for the management
20 of angiogenesis dependent diseases, which include arthritic conditions and solid tumour growth as well as psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angiofibromas and hemangiomas.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 99/00072

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C327/42 C07C327/44 C07D209/20 A61K31/16 A61K31/195
A61K31/655

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 214 639 A (SEARLE) 18 March 1987 cited in the application see page 2 - page 6 ---	1,10
A	EP 0 489 579 A (CELLTECH) 10 June 1992 cited in the application see page 2 ---	1,10
A	WO 96 16931 A (BRITISH BIOTECH PHARMACEUTICALS) 6 June 1996 cited in the application see page 8 -----	1,10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 May 1999

Date of mailing of the international search report

20/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte. Jonal Application No

PCT/DK 99/00072

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0214639 A	18-03-1987	US 4599361 A	08-07-1986
		US 4743587 A	10-05-1988
		AT 53573 T	15-06-1990
		AU 588362 B	14-09-1989
		AU 6240886 A	12-03-1987
		CA 1329397 A	10-05-1994
		DK 169029 B	01-08-1994
		FI 863607 A, B,	11-03-1987
		GR 862286 A	12-01-1987
		IE 58770 B	03-11-1993
		JP 2029563 C	19-03-1996
		JP 7064800 B	12-07-1995
		JP 62103052 A	13-05-1987
		PH 24182 A	22-03-1990
		PT 83328 A, B	01-10-1988
EP 0489579 A	10-06-1992	AT 120182 T	15-04-1995
		AT 120451 T	15-04-1995
		AU 652793 B	08-09-1994
		AU 9017391 A	25-06-1992
		AU 652596 B	01-09-1994
		AU 9023391 A	25-06-1992
		CA 2073510 A	04-06-1992
		CA 2073513 A	04-06-1992
		DE 69108363 D	27-04-1995
		DE 69108363 T	31-08-1995
		DE 69108529 D	04-05-1995
		DE 69108529 T	30-11-1995
		DK 489579 T	12-06-1995
		EP 0489577 A	10-06-1992
		ES 2069833 T	16-05-1995
		FI 923494 A	03-08-1992
		FI 923495 A	03-08-1992
		WO 9209564 A	11-06-1992
		WO 9209565 A	11-06-1992
		GB 2255339 A, B	04-11-1992
		GB 2255340 A, B	04-11-1992
		GR 3015567 T	30-06-1995
		HU 61973 A	29-03-1993
		JP 5503719 T	17-06-1993
		JP 5503720 T	17-06-1993
		US 5889058 A	30-03-1999
		US 5300501 A	05-04-1994
		IE 70429 B	27-11-1996
WO 9616931 A	06-06-1996	AU 688164 B	05-03-1998
		AU 3933295 A	19-06-1996
		BR 9509823 A	04-11-1997
		CA 2205972 A	06-06-1996
		CN 1166825 A	03-12-1997
		CZ 9701591 A	18-02-1998
		EP 0793641 A	10-09-1997
		FI 972198 A	23-05-1997
		GB 2308844 A, B	09-07-1997
		HU 77221 A	02-03-1998
		JP 11501288 T	02-02-1999
		NO 972379 A	23-05-1997
		NZ 295725 A	28-07-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Jnal Application No

PCT/DK 99/00072

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9616931 A		PL 320292 A	15-09-1997
		SK 65097 A	10-12-1997
		US 5866717 A	02-02-1999
